Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2015-09-01 Regulatory Filings
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement between Ardelyx, Inc. and Sanofi, including details about the original agreement and its termination. There are no financial statements or detailed financial performance data presented, nor is this a full annual or quarterly report. The document is not a presentation, call transcript, or voting result announcement. It is a regulatory filing reporting a significant corporate event. Given the nature of the Form 8-K and the content, the appropriate classification is Regulatory Filings (RNS). The document length is short (2722 characters), consistent with a regulatory announcement rather than a full report. Confidence is high due to the clear identification as a Form 8-K and the content matching typical 8-K disclosures.
2015-09-01 English
FORM 4
Director's Dealing
2015-08-27 English
FORM 10-Q
Interim / Quarterly Report Q2 2015
2015-08-12 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company announced its financial results for the quarter ended June 30, 2015. It also references a press release as Exhibit 99.1 containing the full text of the announcement. The document length is 2694 characters, which is relatively short and primarily serves as an announcement of quarterly financial results rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). This document fits that description as it announces quarterly results and includes a press release but does not contain comprehensive financial data or analysis itself.
2015-08-12 English
FORM 4
Director's Dealing
2015-08-11 English
FORM 4
Director's Dealing
2015-08-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.